bioMérieux launches antibody test for
31 October 2012
bioMérieux has launched the new CE-marked VIDAS Anti-HCV test for
the detection of antibodies to the hepatitis C virus (HCV). This
extends the company’s product range to provide a complete test menu
for hepatitis A, B and C.
In conjunction with other clinical information, the VIDAS
Anti-HCV test assists in the diagnosis of HCV in individuals with
symptoms of – or who at risk from – hepatitis C infection, and can
be used in combination with VIDAS HAV and HBV assays to form a test
panel for the differential diagnosis of viral hepatitis.
The VIDAS Anti-HCV assay, developed on the successful VIDAS
automated immunoassay platform, is an enzyme-linked fluorescent
assay (ELFA) that uses core, NS3 and NS4 antigens for the
qualitative detection of antibodies to hepatitis C in human serum or
This easy-to-use test is performed with just 100 µl of sample.
Results are generated in only 40 minutes and, with no grey zone,
data interpretation is simple. All six HCV genotypes can be
detected, with a specificity of 99.61 % and sensitivity of 99.77 %.
The all-inclusive VIDAS Anti-HCV kit is available in a convenient 60
test pack size comprising single dose tests, providing a
cost-effective solution to screening for hepatitis C.